Leah Tanner

Leah Tanner

Auto-generated profile, based on publicly available information

Leah Tanner

Headspace, Santa Monica, CA, United States

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2024 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
CCChristine Callahan
Christine Callahan
JKJustin Kimber
Justin Kimber
EHEmily Hu
Emily Hu
LTLeah Tanner
Leah Tanner
SKSarah Kunkle
Sarah Kunkle
Background: Perceived stress in the United States has drastically increased since the COVID-19 pandemic and is associated with negative mental health outcomes such as depression and anxiety. Digital mental health (DMH) interventions are efficacious tools to address negative mental health outcomes and have helped reduce the severity of psychological symptoms, such as anxiety, depression, and perceived stress, compared to waitlist controls. Although DMH tools have been studied in controlled settings, less is known about the real-world evidence of such interventions. Objective: This study aimed to (1) characterize patterns in baseline perceived stress and changes in perceived stress among Headspace members with moderate and severe baseline perceived stress and (2) examine associations between engagement with Headspace content and changes in perceived stress (ie, evaluate whether there is a dose-response relationship). Methods: We evaluated real-world perceived stress and engagement data at 2 time points among Headspace app members with baseline moderate and severe perceived stress. Perceived stress was measured using the Perceived Stress Scale (PSS-10) and engagement using active days and active minutes engaged with Headspace as well as the number of user sessions. Descriptive statistics were computed for all variables. Correlations between baseline and follow-up scores, percent change in PSS-10 scores, days between PSS-10 use, active days, active days per week, active minutes, active minutes per day, sessions, and sessions per week were evaluated. We used t tests to investigate differences in the abovementioned parameters between (1) participants who did and those who did not see improvements in PSS-10 scores (yes vs no improvement) and (2) participants who saw ≥30% improvement versus those who saw a <30% improvement in PSS-10 scores. Results: Overall, 21,088 Headspace members were included in these analyses. On average, members saw a 23.52% decrease in PSS-10 scores from baseline to follow-up. On average, members had 2.42 (SD 1.76) active days per week and 25.89 (SD 33.40) active minutes per day, and completed 7.11 (SD 8.34) sessions per week. t tests suggest that members who saw improvements in PSS-10 scores from baseline to follow-up had significantly higher baseline PSS-10 scores (Cohen d =0.56), more active days per week (Cohen d =0.33), and more sessions per week (Cohen d =0.27) than those who did not see improvements in PSS-10 scores (all P <.001). Additional t tests suggest that members with ≥30% improvement in PSS-10 scores had significantly higher baseline PSS-10 scores (Cohen d =0.35), more active days per week (Cohen d =0.36), and more sessions per week (Cohen d =0.31) than those with a >30% improvement (all P <.001). Conclusions: Real-world use of Headspace is associated with decreased perceived stress. Furthermore, data suggest that more engagement, specifically weekly active days and sessions, is associated with a greater likelihood of stress reduction.

23 April 2025 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
WSWalter Staiano
Walter Staiano
CCChristine Callahan
Christine Callahan
MDMichelle Davis
Michelle Davis
LTLeah Tanner
Leah Tanner
CCChelsea Coe
Chelsea Coe
UKUlrich Kirk
Ulrich Kirk
Background: Insomnia is the most commonly reported sleep disturbance and significantly impacts mental health and quality of life. Traditional treatments for insomnia include pharmacological interventions or cognitive behavioral therapy for insomnia (CBT-I), but these options may not be accessible to everyone who needs treatment. Objective: This study aims to assess the effectiveness of the app-based Headspace Sleep Program in adults with clinical insomnia on sleep disturbance and mental health outcomes, compared with a waitlist control group. Methods: This randomized controlled trial included 132 adults with clinical insomnia who were assigned to either the Headspace Sleep Program (an 18-session self-guided, in-app program utilizing CBT-I techniques augmented by mindfulness) or a waitlist control group. Sleep disturbance outcomes were assessed by changes in insomnia symptoms (measured using the Insomnia Severity Index) and sleep efficiency (measured via sleep diary and actigraphy). Mental health outcomes included perceived stress (measured by the 10-item Perceived Stress Scale), depressive symptoms (measured by the 8-item Patient Health Questionnaire), sleep quality (measured by the Pittsburgh Sleep Quality Index), anxiety symptoms (measured by the 7-item Generalized Anxiety Disorder Scale), and mindfulness (measured by the Mindful Attention Awareness Scale). Changes from baseline to postintervention and follow-up were assessed for each outcome. Results: Participants had a mean (SD) age of 37.2 (10.6) years, with 69 out of 132 (52.3%) identifying as female. Those randomized to the Headspace Sleep Program group experienced significantly greater improvements in insomnia symptoms from baseline to postintervention and follow-up compared with participants in the waitlist control group (P<.001, η²p=0.107). Improvements from baseline to postintervention and follow-up were also observed in the Headspace Sleep Program group for sleep efficiency, as measured by both sleep diary (P=.01, η²p=.03) and actigraphy outcomes (P=.01, η²p=.03). Participants in the Headspace Sleep Program group showed greater improvements in insomnia remission rates (8/66, 12%, at postintervention and 9/66, 14%, at follow-up) and treatment response (11/66, 17%, at postintervention and 15/66, 23%, at follow-up) compared with the control group (remission rate 2/66, 3%, at postintervention and 0/66, 0%, at follow-up; treatment response 3/66, 5%, at postintervention and 1/66, 2%, at follow-up). The results suggest significant improvements in depressive symptoms (P=.01, η²p=.04), anxiety symptoms (P=.02, η²p=.02), and mindfulness (P=.01, η²p=.03) in the Headspace Sleep Program group. Conclusions: The Headspace Sleep Program is an effective intervention for improving sleep disturbances in adults with clinical insomnia. Trial Registration: ClinicalTrials.gov NCT05872672; https://clinicaltrials.gov/ct2/show/NCT05872672

13 February 2026 in JMIR Formative Research
Verified
Journal Article
Open access
CCChristine Callahan
Christine Callahan
LTLeah Tanner
Leah Tanner
CCChelsea Coe
Chelsea Coe
MDMichelle Davis
Michelle Davis
JGJenna Glover
Jenna Glover
SKSarah Kunkle
Sarah Kunkle
Background: The rapid acceleration of large language models (LLMs) creates opportunities to expand the accessibility of mental health support; however, general artificial intelligence (AI) tools lack safety guardrails, evidence-based practices, and medical regulation compliance, which may result in misinformation and failing to escalate care in crises. In contrast, Ebb, Headspace’s conversational AI tool (CAI tool), was purpose-built by clinical psychologists and research experts using motivational interviewing techniques for subclinical guidance, incorporating clinically backed safety mechanisms. Objective: This study aimed to (1) understand Headspace members’ sentiment toward AI and expectations for a mental health CAI tool, (2) evaluate real-world use of Headspace’s CAI tool, and (3) understand how members perceive a CAI tool fitting into their mental health journey. Methods: This was a multiple method study using three data sources including Headspace members: (1) cross-sectional survey (n=482) assessing demographics, AI use, and the Artificial Intelligence Attitude Scale-4 (AIAS-4); (2) real-world engagement descriptive analysis (n=393,969) assessing session and message counts, retention, and conversation themes; and (3) diary study (n=15) exploring the CAI tool’s role within members’ mental health journey. App engagement was compared between CAI tool 1.0 and CAI tool 2.0, where CAI tool 2.0 featured enhanced LLM conversational prompts, comprehensive memory, woven content recommendations, and more robust safety detection. Results: While the majority of survey respondents used and would continue to use general AI tools, overall attitudes toward AI remained neutral (AIAS-4 mean 5.7, SD 2.2, range 1-10). Survey results suggest that members viewed the CAI tool as a guide to navigate to mental health resources and Headspace content and provide in-the-moment support. Members emphasized the need for data safety and ethics transparency, clinical guidelines structure, and for the CAI tool to be a resource in addition to human-delivered mental health care, not a replacement. Real-world CAI tool use showed strong engagement across 393,969 Headspace members. The product evolution to CAI tool 2.0 led to increased retention (77,894/153,249, 50.8% completed 2 sessions within 7 days vs 68,701/240,720, 28.5% for CAI tool 1.0) and higher positive conversation ratings (37,819/40,449, 93.5% vs 94,308/104,323, 90.4%). Retained CAI tool 2.0 users showed greater retention (6.1 sessions per user) compared to all CAI tool 2.0 users (2.9 sessions per user) and CAI tool 1.0 (2.4 sessions per user). Diary study results suggest that members imagined using the CAI tool when feeling stress or anxiety and during morning routines, commutes, or while winding down at night. Conclusions: Results emphasize the necessity of research-backed, purpose-built mental health AI products with minimum viable safeguards, including (1) transparent labeling of intended use, benefits, and limitations; (2) safety by design principles to monitor for overuse, detect risk, and flag needs for escalation; and (3) child and adolescent safeguards.

23 October 2025 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
WSWalter Staiano
Walter Staiano
CCChristine E Callahan
Christine E Callahan
MDMichelle Davis
Michelle Davis
LTLeah Tanner
Leah Tanner
SKSarah Kunkle
Sarah Kunkle
UKUlrich Kirk
Ulrich Kirk
Background: Anxiety and depressive disorders affect hundreds of millions globally, with substantial barriers limiting access to evidence-based treatments like cognitive behavioral therapy. Digital mental health interventions offer potential solutions to improve access to support. However, evidence of efficacy through randomized controlled trials is essential for clinical adoption. Objective: This study evaluated the efficacy of the Headspace Anxiety and Depression Program, a digitally delivered 21-session intervention grounded in the Unified Protocol that integrates cognitive behavioral and mindfulness-based strategies to target common drivers of emotional disorders, compared to a waitlist control group. Primary aims were to assess reductions in anxiety (Generalized Anxiety Disorder-7 [GAD-7]) and depression (Patient Health Questionnaire-8 [PHQ-8]) symptoms. Secondary aims examined improvements in sleep quality (Pittsburgh Sleep Quality Index), perceived stress (Perceived Stress Scale-10), mindfulness (Mindful Attention Awareness Scale), and overall well-being (Warwick-Edinburgh Mental Well-Being Scale), as well as clinical remission and treatment response rates. Methods: A fully remote, 2-arm parallel-group randomized controlled trial was conducted with 168 participants (aged ≥18 years) who had clinically significant anxiety (GAD-7≥10) or depression symptoms (PHQ-8≥10). Participants were randomized to either the Headspace Anxiety and Depression Program (n=84) or waitlist control (n=84). The intervention consisted of 21 daily sessions (5-10 minutes each) delivered via the Headspace app. Primary (GAD-7 and PHQ-8) and secondary outcomes (Pittsburgh Sleep Quality Index, Perceived Stress Scale-10, Mindful Attention Awareness Scale, and Warwick-Edinburgh Mental Well-Being Scale) were assessed at baseline, postintervention, and a 3-week follow-up using intention-to-treat analysis with mixed-model ANOVAs. Results: Study retention was high, with the majority (154/168, 91.7%) of participants completing the 3-week follow-up visit, and no serious adverse events were reported. Intervention adherence was high, with 82.1% (69/84) in the intervention group completing all 21 sessions. Significant group×time interactions were observed for both primary outcomes (P<.001). The Headspace group showed substantial reductions in anxiety symptoms (GAD-7: 34.5% reduction from baseline: mean 11.9, SD 2.8 to follow-up: mean 7.8, SD 2.3; η2p=0.350) and depression symptoms (PHQ-8: 33.9% reduction from baseline: mean 12.1, SD 2.8 to follow-up: mean 8.0, SD 2.0; η2p=0.370), while the control group did not show significant reductions. Combined anxiety and depression remission rates were significantly higher in the Headspace group (18/84, 21.4%) versus controls (7/84, 8.3%; P=.03), as were treatment response rates (23/84, 27.3% vs 2/84, 2.3%; P=.03). Participants in the Headspace group also demonstrated significant improvements in secondary outcomes, including sleep quality (30.2% improvement), perceived stress (13.2% reduction), mindfulness (10.3% increase), and mental well-being (10.7% increase). Conclusions: The Headspace Anxiety and Depression Program demonstrated significant efficacy in reducing anxiety and depression symptoms comparable to established treatments. Benefits were sustained at the 3-week follow-up. These findings support the potential of evidence-based transdiagnostic digital mental health interventions to address critical gaps in mental health care delivery. Trial Registration: ClinicalTrials.gov NCT06434883; https://clinicaltrials.gov/study/NCT06434883

11 November 2024 in JMIR Preprints
Verified
Preprint
Open access
WSWalter Staiano
Walter Staiano
CCChristine Callahan
Christine Callahan
MDMichelle Davis
Michelle Davis
LTLeah Tanner
Leah Tanner
CCChelsea Coe
Chelsea Coe
UKUlrich Kirk
Ulrich Kirk
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Insomnia is the most commonly reported sleep disturbance and significantly impacts mental health and quality of life. Traditional treatments for insomnia include pharmacological interventions or cognitive behavioral therapy for insomnia (CBT-I), but these options may not be accessible to everyone who needs treatment. Objective: This study aims to assess the effectiveness of the app-based Headspace Sleep Program in adults with clinical insomnia on sleep disturbance and mental health outcomes, compared with a waitlist control group. Methods: This randomized controlled trial included 132 adults with clinical insomnia who were assigned to either the Headspace Sleep Program (an 18-session self-guided, in-app program utilizing CBT-I techniques augmented by mindfulness) or a waitlist control group. Sleep disturbance outcomes were assessed by changes in insomnia symptoms (measured using the Insomnia Severity Index) and sleep efficiency (measured via sleep diary and actigraphy). Mental health outcomes included perceived stress (measured by the 10-item Perceived Stress Scale), depressive symptoms (measured by the 8-item Patient Health Questionnaire), sleep quality (measured by the Pittsburgh Sleep Quality Index), anxiety symptoms (measured by the 7-item Generalized Anxiety Disorder Scale), and mindfulness (measured by the Mindful Attention Awareness Scale). Changes from baseline to postintervention and follow-up were assessed for each outcome. Results: Participants had a mean (SD) age of 37.2 (10.6) years, with 69 out of 132 (52.3%) identifying as female. Those randomized to the Headspace Sleep Program group experienced significantly greater improvements in insomnia symptoms from baseline to postintervention and follow-up compared with participants in the waitlist control group (P<.001, η²p=0.107). Improvements from baseline to postintervention and follow-up were also observed in the Headspace Sleep Program group for sleep efficiency, as measured by both sleep diary (P=.01, η²p=.03) and actigraphy outcomes (P=.01, η²p=.03). Participants in the Headspace Sleep Program group showed greater improvements in insomnia remission rates (8/66, 12%, at postintervention and 9/66, 14%, at follow-up) and treatment response (11/66, 17%, at postintervention and 15/66, 23%, at follow-up) compared with the control group (remission rate 2/66, 3%, at postintervention and 0/66, 0%, at follow-up; treatment response 3/66, 5%, at postintervention and 1/66, 2%, at follow-up). The results suggest significant improvements in depressive symptoms (P=.01, η²p=.04), anxiety symptoms (P=.02, η²p=.02), and mindfulness (P=.01, η²p=.03) in the Headspace Sleep Program group. Conclusions: The Headspace Sleep Program is an effective intervention for improving sleep disturbances in adults with clinical insomnia. Trial Registration: ClinicalTrials.gov NCT05872672; https://clinicaltrials.gov/ct2/show/NCT05872672

3 November 2025 in JMIR Preprints
Verified
Preprint
Open access
CCChristine Callahan
Christine Callahan
LTLeah Tanner
Leah Tanner
CCChelsea Coe
Chelsea Coe
MDMichelle Davis
Michelle Davis
JGJenna Glover
Jenna Glover
SKSarah Kunkle
Sarah Kunkle
BACKGROUND The rapid acceleration of large language models (LLMs) creates opportunities to expand the accessibility of mental health support; however, general artificial intelligence (AI) tools lack safety guardrails, evidence-based practices, and medical regulation compliance, which may result in misinformation and failing to escalate care in crises. In contrast, Ebb, Headspace’s conversational AI tool (CAI tool), was purpose-built by clinical psychologists and research experts using motivational interviewing techniques for subclinical guidance, incorporating clinically backed safety mechanisms. OBJECTIVE This study aimed to (1) understand Headspace members’ sentiment toward AI and expectations for a mental health CAI tool, (2) evaluate real-world use of Headspace’s CAI tool, and (3) understand how members perceive a CAI tool fitting into their mental health journey. METHODS This was a multiple method study using three data sources including Headspace members: (1) cross-sectional survey (n=482) assessing demographics, AI use, and the Artificial Intelligence Attitude Scale-4 (AIAS-4); (2) real-world engagement descriptive analysis (n=393,969) assessing session and message counts, retention, and conversation themes; and (3) diary study (n=15) exploring the CAI tool’s role within members’ mental health journey. App engagement was compared between CAI tool 1.0 and CAI tool 2.0, where CAI tool 2.0 featured enhanced LLM conversational prompts, comprehensive memory, woven content recommendations, and more robust safety detection. RESULTS While the majority of survey respondents used and would continue to use general AI tools, overall attitudes toward AI remained neutral (AIAS-4 mean 5.7, SD 2.2, range 1-10). Survey results suggest that members viewed the CAI tool as a guide to navigate to mental health resources and Headspace content and provide in-the-moment support. Members emphasized the need for data safety and ethics transparency, clinical guidelines structure, and for the CAI tool to be a resource in addition to human-delivered mental health care, not a replacement. Real-world CAI tool use showed strong engagement across 393,969 Headspace members. The product evolution to CAI tool 2.0 led to increased retention (77,894/153,249, 50.8% completed 2 sessions within 7 days vs 68,701/240,720, 28.5% for CAI tool 1.0) and higher positive conversation ratings (37,819/40,449, 93.5% vs 94,308/104,323, 90.4%). Retained CAI tool 2.0 users showed greater retention (6.1 sessions per user) compared to all CAI tool 2.0 users (2.9 sessions per user) and CAI tool 1.0 (2.4 sessions per user). Diary study results suggest that members imagined using the CAI tool when feeling stress or anxiety and during morning routines, commutes, or while winding down at night. CONCLUSIONS Results emphasize the necessity of research-backed, purpose-built mental health AI products with minimum viable safeguards, including (1) transparent labeling of intended use, benefits, and limitations; (2) safety by design principles to monitor for overuse, detect risk, and flag needs for escalation; and (3) child and adolescent safeguards.